Every FDA drug approval from 2024: Fewer nods, but long-awaited treatments cross the finish line

2024’s novel drug approvals offered a wide array of new cancer drugs, rare disease treatments, a potential Alzheimer’s blockbuster, and about 10 fewer approvals than …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Pharmalittle: We’re reading about a Biosecure Act setback, a judge ordering release of Covid vaccine data, and more

Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because the time has come to return

December 9, 2024

Molnupiravir reduces long-term COVID-19 symptoms but shows limited impact on hospitalizations

Molnupiravir treatment for COVID-19 shows modest long-term benefits, reducing symptoms and improving well-being at three and six months. However, the differences were small, with no

September 12, 2024

PolyPeptide appoints Chief Commercial Officer – Biotech Investments

PolyPeptide Group / Key word(s): Personnel PolyPeptide appoints Chief Commercial Officer 08.08.2024 / 20:00 CET/CEST Media release PolyPeptide appoints Chief Commercial Officer Baar, 8 August

August 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.